Immunodeficiency disease
MONDO:0021094Disease in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
Also known as: immuno-deficiency, immunodeficiency, immunodeficiency disorder, immunodeficiency syndrome
779 clinical trials for this condition and its sub-types, 55 tagged with Immunodeficiency disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Immunodeficiency disease
-
T-cell immunodeficiency 4 trials · 484 incl. sub-types
3 sub-types
- AIDS 463 trials
- Congenital T-cell immunodeficiency 0 trials · 13 incl. sub-types Sub-types →
- Idiopathic CD4-positive T-lymphocytopenia 6 trials
-
B cell deficiency 5 trials · 86 incl. sub-types
5 sub-types
- Agammaglobulinemia 16 trials · 52 incl. sub-types Sub-types →
- Hyperimmunoglobulin syndrome 0 trials · 34 incl. sub-types Sub-types →
- Selective immunoglobulin deficiency disease 1 trial · 4 incl. sub-types Sub-types →
- PAX5-related B lymphopenia and autism spectrum disorder 0 trials
- Immunoglobulin beta deficiency 0 trials
-
Combined immunodeficiency 3 trials · 57 incl. sub-types
33 sub-types
- Severe combined immunodeficiency 24 trials · 37 incl. sub-types Sub-types →
- Ataxia telangiectasia 11 trials Sub-types →
- Wiskott-Aldrich syndrome 10 trials
- X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia 2 trials
- Combined immunodeficiency due to CRAC channel dysfunction 1 trial Sub-types →
- Combined immunodeficiency due to ZAP70 deficiency 1 trial
- Non-SCID combined immunodeficiency 0 trials · 1 incl. sub-types Sub-types →
- IRF4-related combined immunodeficiency 0 trials
- MHC class I deficiency 0 trials Sub-types →
- NFATC1-related combined immunodeficiency 0 trials
- POLD3-related combined immunodeficiency 0 trials
- RAC2-related combined immunodeficiency-bronchiectasis-cancer-predisposing syndrome 0 trials Sub-types →
- Autosomal dominant combined immunodeficiency due to ERBIN deficiency 0 trials
- Autosomal dominant combined immunodeficiency due to partial IL6ST deficiency 0 trials
- Autosomal recessive combined immunodeficiency due to IL6R deficiency 0 trials
- Autosomal recessive combined immunodeficiency due to complete IL6ST deficiency 0 trials
- Autosomal recessive combined immunodeficiency due to partial IL6ST deficiency 0 trials
- Combined immunodeficiency due to CD3gamma deficiency 0 trials
- Combined immunodeficiency due to CTPS1 deficiency 0 trials
- Combined immunodeficiency due to GINS1 deficiency 0 trials
- Combined immunodeficiency due to MALT1 deficiency 0 trials
- Combined immunodeficiency due to OX40 deficiency 0 trials
- Combined immunodeficiency due to POLE2 deficiency 0 trials
- Combined immunodeficiency due to RELA haploinsufficiency 0 trials
- Combined immunodeficiency due to STK4 deficiency 0 trials
- Combined immunodeficiency due to TBX1 deficiency 0 trials
- Combined immunodeficiency due to dimerization defective IKAROS mutation 0 trials
- Combined immunodeficiency due to moesin deficiency 0 trials
- Combined immunodeficiency syndrome 0 trials Sub-types →
- Combined immunodeficiency with low Ig due to BCL10 deficiency 0 trials
- Combined immunodeficiency-hypogammaglobulinemia-skeletal anomalies syndrome due to IKBKA deficiency 0 trials
- Early-onset combined immunodeficiency with low ig due to dominant negative IKAROS mutation 0 trials
- Late-onset combined immunodeficiency due to ICOSL deficiency 0 trials
-
Complement deficiency 2 trials · 28 incl. sub-types
8 sub-types
- Atypical hemolytic-uremic syndrome 19 trials Sub-types →
- Classic complement early component deficiency 0 trials · 7 incl. sub-types Sub-types →
- Disorder of lectin complement activation pathway 0 trials · 1 incl. sub-types Sub-types →
- Complement factor I deficiency 0 trials
- Complement receptor deficiency 0 trials
- Immunodeficiency due to a classical component pathway complement deficiency 0 trials Sub-types →
- Immunodeficiency due to a late component of complement deficiency 0 trials Sub-types →
- Recurrent Neisseria infections due to factor D deficiency 0 trials
-
X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types
2 sub-types
-
GATA2 deficiency with susceptibility to MDS/AML 5 trials · 8 incl. sub-types
2 sub-types
-
Idiopathic CD4 lymphocytopenia 7 trials
-
IKBKG-related immunodeficiency with or without ectodermal dysplasia 0 trials · 4 incl. sub-types
3 sub-types
-
IRF4-related immune disorder 1 trial
2 sub-types
- IRF4-related combined immunodeficiency 0 trials
- Immunodeficiency 131 0 trials
-
Immunodeficiency 23 1 trial
-
Immunodeficiency 31B 1 trial
-
DOCK2 deficiency 0 trials
-
FADD-related immunodeficiency 0 trials
-
FASLG-related immunodeficiency 0 trials
-
FNIP1-associated syndrome 0 trials
-
Shwachman-Diamond syndrome 1 0 trials
-
TNFRSF9-related immunodeficiency 0 trials
1 sub-type
-
Wiskott-Aldrich syndrome 2 0 trials
-
Hatipoglu immunodeficiency syndrome 0 trials
-
Hypoproteinemia, hypercatabolic 0 trials
-
Immunodeficiency 102 0 trials
-
Immunodeficiency 112 0 trials
-
Immunodeficiency 117 0 trials
-
Immunodeficiency 118 0 trials
-
Immunodeficiency 119 0 trials
-
Immunodeficiency 122 0 trials
-
Immunodeficiency 125 0 trials
-
Immunodeficiency 127 0 trials
-
Immunodeficiency 128 0 trials
-
Immunodeficiency 132b 0 trials
-
Immunodeficiency 15a 0 trials
-
Immunodeficiency 35 0 trials
-
Immunodeficiency 45 0 trials
-
Immunodeficiency 53 0 trials
-
Immunodeficiency 57 0 trials
-
Immunodeficiency 60 0 trials
-
Immunodeficiency 62 0 trials
-
Immunodeficiency 64 0 trials
-
Immunodeficiency 66 0 trials
-
Immunodeficiency 67 0 trials
-
Immunodeficiency 69 0 trials
-
Immunodeficiency 70 0 trials
-
Immunodeficiency 75 0 trials
-
Immunodeficiency 76 0 trials
-
Immunodeficiency 77 0 trials
-
Immunodeficiency 81 0 trials
-
Immunodeficiency 84 0 trials
-
Immunodeficiency 85 and autoimmunity 0 trials
-
Immunodeficiency 86 0 trials
-
Immunodeficiency 87 and autoimmunity 0 trials
-
Immunodeficiency 88 0 trials
-
Immunodeficiency 89 and autoimmunity 0 trials
-
Immunodeficiency 92 0 trials
-
Immunodeficiency 95 0 trials
-
Immunodeficiency 96 0 trials
-
Lymphoproliferative syndrome 1 0 trials
Most studied deeper sub-types
-
Could a daily pill stop hereditary angioedema attacks?
Disease control Stopped earlyThis trial tests whether an experimental oral medication, deucrictibant, can reduce the number of swelling attacks in people with hereditary angioedema (HAE) types I and II. Participants take either a low or high dose of the drug or a placebo for 12 weeks, and then may continue o…
Phase 2 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
HIV drug switch may boost heart health and trim body fat
Disease control Stopped earlyThis study looked at whether switching from a standard HIV drug combination to a different one (Delstrigo) could improve cholesterol, body fat, and blood sugar in people with HIV. The study planned to enroll 60 adults whose HIV was already well-controlled. Participants were rando…
Phase 4 • Sponsor: Chelsea and Westminster NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Experimental drug for rare skin disease fails to reach goal
Disease control Stopped earlyThis early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control Stopped earlyThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase 3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
HIV pill combo fails to slim belly fat in early trial
Disease control Stopped earlyThis study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New stem cell method aims to protect kids with rare immune disease
Disease control Stopped earlyThis study tested a way to improve stem cell transplants for children with combined immunodeficiency (CID), a condition where the immune system doesn't work properly. The approach removed certain naive cells from the donor stem cells to try to prevent graft-versus-host disease (a…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental drug shows promise for rare immune disorder, but study cut short
Disease control Stopped earlyThis study tested the long-term safety and effectiveness of a drug called CDZ173 in people with APDS/PASLI, a rare genetic condition that causes a weak immune system and swollen lymph nodes. The 37 participants had already taken CDZ173 or a similar drug in a previous study. The t…
Phase 2/3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control Stopped earlyThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase 2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Hope for rare skin disease: new drug shows promise in trial
Disease control Stopped earlyThis study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…
Phase 2/3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising aHUS drug trial stalls after only 6 patients enrolled
Disease control Stopped earlyThis study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…
Phase 3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental HIV therapy aims to free patients from daily pills
Disease control Stopped earlyThis early-stage trial tests two experimental vaccines, HB-502 and HB-501, designed to teach the immune system to recognize and attack HIV. The study includes 30 people with HIV who are already on suppressive antiretroviral therapy. Participants receive injections every 8 weeks f…
Phase 1 • Sponsor: Hookipa Biotech GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
HIV drug extension study halted early: what happened?
Disease control Stopped earlyThis study looked at whether weekly injections of PRO 140, taken with standard HIV medications, could keep the virus under control over the long term. It enrolled 43 people who had already completed an earlier PRO 140 study and had undetectable virus levels. The study was termina…
Phase 2/3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New program aims to boost HIV medication adherence for medicaid patients
Disease control Stopped earlyThis study tested a program to help Virginia Medicaid enrollees with HIV fill their antiretroviral prescriptions on time. The program offered support from providers, pharmacies, and community groups, with extra help for those who were very late refilling. Only 4 people enrolled b…
Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
HIV Antibody-Only therapy falls short in Long-Term trial
Disease control Stopped earlyThis study tested whether a single antibody called PRO 140 could keep HIV under control in 20 adults who had been stable on standard combination therapy. Participants stopped their usual HIV pills and received only PRO 140 infusions. The trial was stopped early, and the main goal…
Phase 2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Monthly HIV prevention pill tested in women – study halted early
Prevention Stopped earlyThis study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so results are limited. The goal was to offer a more convenient prevention option.
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
Antibody shield for the vulnerable: COVID-19 prevention trial in immunocompromised
Prevention Stopped earlyThis study tested whether a combination of antibodies (casirivimab+imdevimab) could prevent COVID-19 in people with weakened immune systems, such as transplant recipients or cancer patients. Participants received either the antibodies or a placebo as a shot under the skin. The tr…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC
-
Can an eczema drug calm a rare genetic skin disease?
Symptom relief Stopped earlyNetherton syndrome is a rare genetic disorder that causes red, scaly, inflamed skin and intense itching. No targeted treatments exist, so researchers are testing dupilumab, an injectable drug already used for eczema, against a placebo in 10 adults with moderate to severe Netherto…
Phase 2/3 • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Sep 21, 2026 18:00 UTC
-
Could a nerve pain drug and exercise ease long COVID fatigue?
Symptom relief Stopped earlyThis study tests whether the drug pregabalin, alone or with a rehabilitation program, can reduce chronic fatigue in people with post-COVID syndrome. Participants are adults aged 18 to 65 who had COVID-19 at least six months ago and still feel very tired. The trial compares four g…
Phase 2 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Personalized exercise trial for chronic fatigue ends early
Symptom relief Stopped earlyThis study tested whether a personalized exercise program could reduce fatigue in people with chronic fatigue syndrome. About 101 participants were planned, but the trial was terminated early. The approach involved tailoring aerobic and resistance exercises based on weekly fatigu…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Brain zaps for pain and fatigue: a quick fix?
Symptom relief Stopped earlyThis study looked at whether a brief, noninvasive brain stimulation technique called tDCS could immediately reduce pain and improve function in people with fibromyalgia or chronic fatigue syndrome. About 20 participants received one session, and researchers measured changes in pa…
Sponsor: Hospital Donostia • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Rare skin disease study seeks to understand netherton syndrome
Knowledge-focused Stopped earlyThis study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Scientists investigate mpox in severely weakened immune systems
Knowledge-focused Stopped earlyThis study looked at how the mpox virus spreads and how the immune system responds in people with advanced HIV. Researchers tracked the virus in different body samples and measured immune markers to better understand severe illness. The goal is to use these findings to improve tr…
Sponsor: Centers for Disease Control and Prevention • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Web tool aims to boost HIV testing among black women in the south
Knowledge-focused Stopped earlyThis study tested a web-based program to help Black women in Texas use HIV and STI home tests and connect to treatment or PrEP. The program included five sessions with goal-setting and action plans. Only 31 women enrolled before the study was stopped early, so the findings are li…
Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
HIV study tracks daily movement in NYC
Knowledge-focused Stopped earlyThis study looked at how much physical activity and sitting time people with HIV in New York City get. Participants wore a small device called an accelerometer for a week to track their movement. The goal was to understand how activity levels relate to overall health. The study w…
Sponsor: Queens College, The City University of New York • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC